Company Encyclopedia
View More
name
Salarius Pharmaceuticals
SLRX.US
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.
1.868 T
SLRX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Why Is Salarius Pharmaceuticals Stock (SLRX) Up 65% Today?

    Salarius Pharmaceuticals (SLRX) stock surged 66.33% on Wednesday after a significant drop the previous day due to an underwritten public offering of over 2.5 million shares at $1.50 each, raising approximately $7 million. The stock typically rebounds post-offering, and the offering was set to close today. The proceeds will fund clinical development and pay off Decoy's promissory notes. Despite the rally, SLRX is down 96.45% year-to-date and 95.37% over the past year, with heavy trading volume exceeding 27 million shares today.

    Tip Ranks·
    US
    SLRX
    +24.59%
    Tip Ranks·
    US
    SLRX
    +24.59%

    Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?

    Salarius Pharmaceuticals Inc. (SLRX) shares rose 23.65% in after-hours trading to $1.21 following the announcement of a $7 million underwritten public offering. The offering includes 2.51 million common shares and pre-funded warrants for 2.15 million shares at $1.50 each. The completion of the offering is contingent on a merger with Decoy Therapeutics Inc. Despite the after-hours surge, SLRX stock is down 96.25% year-to-date, with a market cap of $1.03 million.

    fidelity·
    US
    SLRX
    +24.59%
    fidelity·
    US
    SLRX
    +24.59%

    SLRX stock has given up its prior gain. Salarius Pharmaceuticals shares were trading higher after the company announced the pricing of a $7 million underwritten public offering.

    benzinga_article·
    US
    SLRX
    +24.59%
    benzinga_article·
    US
    SLRX
    +24.59%

    Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering | SLRX Stock News

    Salarius Pharmaceuticals, Inc. has announced the pricing of a $7 million underwritten public offering, consisting of 2,514,335 shares of common stock and pre-funded warrants for 2,152,331 shares, along with Series A and B Warrants. The offering price is set at $1.50 per share and $1.4999 per pre-funded warrant. The proceeds will be used for clinical development, paying off Decoy's promissory notes, and general corporate purposes. The offering is expected to close around November 12, 2025, pending certain conditions.

    StockTitan·
    US
    SLRX
    +24.59%
    StockTitan·
    US
    SLRX
    +24.59%

    Salarius Pharmaceuticals Inc. Announces Date for Upcoming Annual Stockholders Meeting

    Salarius Pharmaceuticals Inc. has scheduled its 2025 Annual Meeting of Stockholders for December 19, 2025, which will be held as a live audio webcast. This announcement was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice.

    Reuters·
    US
    SLRX
    +24.59%
    Reuters·
    US
    SLRX
    +24.59%